Choosing a weight-management medicine used to mean picking between a handful of modest, short-term pills. In 2026 the picture looks very different. Weekly injections, daily pills built on gut-hormone science, older combination tablets and a pharmacy-shelf option all sit alongside lifestyle programmes, devices and surgery. That is good news for patients, but it also makes the choice harder, and it has created a thriving market in look-alike products, compounded copies and outright fakes.
This guide is organised as a decision aid rather than a list of brand names. We start with what “approved” really means, move through who generally qualifies, compare each class of FDA-approved treatment, and finish with a safety screen and a list of questions to bring to your appointment. If you arrived here after reading about withdrawn drugs, our explainer on Meridia and Reductil regulatory status covers why older products such as sibutramine disappeared.
The Short Version
- “Currently approved” means a regulator has reviewed evidence of benefit and risk for a specific use, and the product is made under quality controls.
- In the U.S., prescription options now include semaglutide (Wegovy injection and pill), tirzepatide (Zepbound), liraglutide (Saxenda), orforglipron (Foundayo), naltrexone-bupropion (Contrave), phentermine-topiramate (Qsymia), orlistat, and short-term phentermine-type appetite suppressants.
- No option is “safe for everyone.” Safety depends on your medical history, other medicines, pregnancy plans and monitoring.
- Be wary of compounded copies, unapproved “research” peptides and supplements that promise prescription-level results.
What “Approved” Means, and Why It Matters
When the U.S. Food and Drug Administration approves a medicine, it has evaluated clinical trial data showing that the drug works for a stated purpose and that its risks are acceptable for the intended population. The approval also covers the manufacturing process, the label and the warnings printed on it. That framework is the main difference between an approved weight-loss medicine and a bottle of capsules sold as a dietary supplement. Supplements do not need FDA approval before they are sold, and the agency has repeatedly found hidden drugs in some of them.
Approval is not a guarantee of suitability. A medicine can be approved, effective and still wrong for you because of a thyroid condition, pregnancy, an interacting drug or a history of pancreatitis. Think of the approved list as a menu of options that deserve a conversation, not a shopping list.
Who Typically Qualifies for Weight-Loss Medication?
Most prescription weight-management labels in adults use the same two thresholds, always alongside a reduced-calorie diet and increased physical activity:
- a body mass index (BMI) of 30 kg/m² or higher, or
- a BMI of 27 kg/m² or higher together with at least one weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol.
Some products have additional or different criteria. Wegovy and Saxenda carry approvals for adolescents aged 12 and over who meet age-specific BMI definitions. Zepbound also holds an approval for moderate-to-severe obstructive sleep apnea in adults with obesity. Your prescriber will use the current label, not this article, to decide what applies to you.
Approved Weight-Management Options at a Glance
| Medicine | Type and how it is taken | Typical role | Key cautions |
|---|---|---|---|
| Wegovy (semaglutide) | GLP-1; weekly injection or daily pill; Wegovy HD is a higher-dose injection | Long-term weight management; also cardiovascular risk reduction in certain adults | Nausea, vomiting, gallbladder problems; thyroid C-cell tumour boxed warning on injectables |
| Zepbound (tirzepatide) | GIP/GLP-1; weekly injection | Long-term weight management; sleep apnea in obesity | GI effects; thyroid C-cell warning; pancreatitis risk |
| Saxenda (liraglutide) | GLP-1; daily injection | Long-term weight management, adults and adolescents 12+ | GI effects; thyroid C-cell warning |
| Foundayo (orforglipron) | Oral GLP-1 agonist; once-daily tablet | Weight loss and maintenance in adults with obesity or overweight with comorbidities | Newest approval (April 2026); follow the label closely |
| Contrave (naltrexone-bupropion) | Oral extended-release tablet | Appetite and craving control | Boxed warning for suicidal thoughts; not for people using opioids or with seizure disorders |
| Qsymia (phentermine-topiramate) | Oral extended-release capsule | Appetite suppression with satiety | Birth-defect risk; controlled substance (C-IV); mood and cognitive effects |
| Orlistat (Xenical; alli at lower strength) | Oral capsule taken with meals | Blocks part of dietary fat absorption | Oily stools, urgency; fat-soluble vitamin absorption |
| Phentermine and similar (Adipex-P, Lomaira) | Oral tablet or capsule | Short-term use only | Raises heart rate and blood pressure; insomnia; controlled substance |
The Gut-Hormone Medicines: Injectables First
The biggest change in obesity medicine over the past several years is the arrival of drugs that imitate gut hormones released after eating. They slow stomach emptying, act on appetite centres in the brain and, in the case of tirzepatide, add a second hormonal signal.
Semaglutide: Wegovy and Wegovy HD
Wegovy, a once-weekly semaglutide injection, was approved for chronic weight management in 2021. In trials it produced average weight reductions of roughly 15 percent of body weight over about 68 weeks when paired with lifestyle support. It later gained an indication to reduce the risk of major cardiovascular events in adults with established heart disease who are overweight or have obesity. In December 2025 the FDA approved a once-daily Wegovy pill, the first oral GLP-1 agonist cleared specifically for chronic weight management, and in March 2026 it approved Wegovy HD, a 7.2 mg injectable dose that produced additional weight reduction in clinical testing.
Tirzepatide: Zepbound
Zepbound, approved in late 2023, activates both GIP and GLP-1 receptors. In its pivotal trial, the highest dose produced average weight loss of about 20 percent, and a head-to-head study against semaglutide found greater loss with tirzepatide (roughly 20 percent versus 14 percent at 72 weeks). Zepbound also became the first prescription medicine approved for obstructive sleep apnea in adults with obesity.
Liraglutide: Saxenda
Saxenda is the older daily-injection GLP-1 option. It produces smaller average weight loss than semaglutide or tirzepatide, but it has the longest track record and an adolescent indication, so it still has a place for some patients, particularly when insurance coverage or availability steers the decision.
What These Injectables Have in Common
Nausea, vomiting, diarrhoea and constipation are the most frequent side effects, usually worst while the dose is being increased. More serious risks include gallbladder disease, pancreatitis, kidney injury from dehydration and, on semaglutide, liraglutide and tirzepatide injectables, a boxed warning about thyroid C-cell tumours seen in rodents. People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not use them. They are not recommended during pregnancy, and many labels advise stopping them before a planned conception. Weight often returns when treatment stops, which is why clinicians increasingly describe these as long-term therapies rather than short courses.
The New Oral GLP-1 Options
For people who dislike injections, two daily oral products now exist. The Wegovy pill delivers semaglutide as a tablet and has dosing rules that usually involve an empty stomach and a small sip of water. Foundayo (orforglipron), approved in April 2026, is a small-molecule oral GLP-1 agonist that its manufacturer describes as taken at any time of day without food or water restrictions. Both are new enough that real-world experience is still accumulating, so reading the current prescribing information and asking about monitoring is especially important. Do not assume a pill is automatically gentler than an injection; the class-level side effects overlap.
Older Oral Medicines That Still Have a Role
Naltrexone-Bupropion (Contrave)
Contrave combines an opioid-receptor blocker with an antidepressant and stimulant-like medicine that affect reward and appetite pathways. Average weight loss in trials was in the range of roughly 5 to 9 percent, depending on the analysis. Because naltrexone blocks opioids, Contrave is not appropriate for anyone taking opioid pain medicines or being treated with opioid agonists. It also carries a boxed warning about suicidal thoughts and behaviour typical of antidepressants, and it should be avoided in uncontrolled hypertension and seizure disorders. Anyone with an opioid-use history should talk through the details with their prescriber. For context on naltrexone’s other uses, see our comparison of naltrexone vs methadone.
Phentermine-Topiramate (Qsymia)
Qsymia pairs a low-dose stimulant appetite suppressant with an anticonvulsant that also affects satiety. Average weight loss at the recommended dose is around 10 percent in trials, making it one of the more effective oral options. The principal safety issue is fetal harm: topiramate has been associated with cleft lip and palate, so people who can become pregnant need pregnancy testing and effective contraception under a risk-mitigation programme. It is a Schedule IV controlled substance, and effects can include tingling, dry mouth, altered taste, mood change and difficulty concentrating.
Orlistat (Xenical and alli)
Orlistat works in the gut by blocking roughly a quarter to a third of the fat in a meal from being absorbed. The prescription capsule is 120 mg; a 60 mg version is sold over the counter as alli. Average added weight loss compared with placebo is modest, and the side effects (oily spotting, urgency, flatulence) tend to teach people to eat lower-fat meals. A daily multivitamin taken at a separate time is usually advised, because fat-soluble vitamins A, D, E and K can be affected. Rare cases of liver injury have been reported, so persistent right-sided abdominal pain, dark urine or yellowing of the skin should prompt medical review.
Phentermine and Similar Short-Term Appetite Suppressants
Phentermine (Adipex-P, Lomaira), benzphetamine, diethylpropion and phendimetrazine are approved only for short-term use, typically a few weeks, even though they are sometimes prescribed for longer by clinicians who weigh the risks case by case. They act like mild stimulants, so they increase heart rate and blood pressure and can cause insomnia, dry mouth and nervousness. They are generally avoided in people with heart disease, uncontrolled hypertension, hyperthyroidism, glaucoma or a history of substance misuse. If you want to compare two commonly searched options, read Phentermine vs Adipex and Bontril vs Adipex.
Approaches That Are Not Pills or Injections
Medication works best as part of a wider plan. Structured behavioural programmes, dietitian-led nutrition counselling, resistance and aerobic exercise, sleep improvement and treatment of conditions such as depression or sleep apnea all influence results. Several of these appear in our own library; for example, our practical guides on protein powders for weight loss and losing chest fat explain how nutrition and training choices fit in.
Other regulated tools include a swallowed hydrogel device that expands in the stomach and, for people with severe obesity, bariatric surgery or endoscopic procedures. For rare genetic forms of obesity, specialised prescription treatments exist and are managed by endocrinologists. These options have their own eligibility rules and are worth discussing with a specialist.
A Safety Screen Before You Start Any Medicine
Whichever option you are considering, bring honest answers to these questions. Each one can change which medicine is appropriate.
Medical History
- Have you had pancreatitis, gallstones, kidney disease, gastroparesis or an eating disorder?
- Do you or any close relative have medullary thyroid cancer or MEN 2?
- Do you have high blood pressure, arrhythmia, coronary disease or a previous stroke?
- Do you have a history of seizures, glaucoma, depression or suicidal thoughts?
Medicines and Substances
- Do you use opioid medicines, buprenorphine or methadone? Contrave is generally unsuitable in these cases.
- Do you take stimulants for ADHD, antidepressants, insulin or sulfonylureas? Dose changes may be needed. Our comparison of Strattera and Adderall is useful background if you use ADHD medicine.
- Do you drink alcohol regularly, or use cannabis or other drugs?
Pregnancy and Breastfeeding
Most weight-loss medicines should not be used during pregnancy. If you might conceive, ask about contraception and about how long a medicine should be stopped beforehand.
Compounded Copies, Counterfeits and “Research Peptides”
Demand for GLP-1 drugs has led to compounded versions, online “telehealth” bundles and products labelled “for research use only.” The FDA has warned about dosing errors with compounded semaglutide and tirzepatide, and notes that there are no approved generic versions of Wegovy despite advertising that implies otherwise. Practical safeguards include:
- filling prescriptions only at licensed pharmacies you can verify;
- checking that the product name, strength and manufacturer match your prescription;
- refusing anything sold without a prescription or consultation;
- learning the correct injection units, because mix-ups between milligrams and “units” have led to overdoses;
- never buying injectables or pills from social-media sellers.
The same caution applies to slimming supplements. The FDA has found sibutramine, the active ingredient of the withdrawn drug Meridia, in products labelled “all natural.” Our audit-style guide, Slimall ingredients and safety, shows how to read those labels.
Four Common Patient Profiles and the Questions They Raise
Every case is individual, but these composite examples show how clinicians typically reason. They are illustrations, not recommendations.
Profile 1: Obesity With Type 2 Diabetes
Because GLP-1 and GIP/GLP-1 medicines lower blood sugar as well as weight, they are frequently considered first. The prescriber may need to reduce insulin or a sulfonylurea to avoid low blood sugar. Eye and kidney status are checked, and the plan includes a strategy for protein intake and muscle preservation.
Profile 2: Obesity With High Blood Pressure and Heart Disease
Medicines that raise heart rate, such as phentermine-type drugs, are usually avoided. Semaglutide has outcome data in this group, which can influence the choice. Blood pressure medicines may need to be lowered as weight drops.
Profile 3: Food Cravings and Emotional Eating
Some clinicians consider naltrexone-bupropion because of its action on reward pathways, provided there is no opioid use, seizure history or uncontrolled hypertension. Screening for depression, binge-eating disorder and substance use is essential, and psychological therapy may be paired with medication.
Profile 4: Possibility of Pregnancy
This is the most restrictive scenario. Qsymia requires reliable contraception, GLP-1 medicines are not recommended in pregnancy, and many labels advise stopping weeks or months before conception. Preconception planning with an obstetric clinician is the safest path.
Cost, Insurance and Access
Cost is often the practical barrier. List prices for newer injectables are high, and coverage varies widely between plans; some insurers require prior authorisation, documented BMI and proof of a lifestyle programme, and some exclude weight-loss drugs altogether. Manufacturer savings programmes, employer plans, Medicaid rules and cash-pay options differ by state and over time, so ask your pharmacy and insurer for current terms rather than relying on a headline price. Cheaper routes are not always safer routes: a price far below the market rate is a reason to double-check the source, particularly for injectables that need cold-chain storage.
Shortages have also affected GLP-1 supply in recent years. If your pharmacy cannot fill a dose, ask your prescriber how to bridge safely instead of improvising with leftover pens, split doses or a different product from an unverified seller.
What to Expect: Results, Side Effects and Follow-Up
Realistic expectations help people stay on course. Average results differ greatly between medicines, and individual responses range from minimal to dramatic. Many labels recommend reassessing after a defined period; for example, some guidance suggests discontinuing a phentermine-topiramate dose if less than 5 percent weight loss is achieved after 12 weeks at the maximum dose. Typical follow-up includes weight, blood pressure, pulse, blood sugar and mood checks, plus a review of side effects and nutrition, especially protein intake and hydration with GLP-1 medicines.
Practical tips that prescribers commonly give include eating smaller, slower meals, avoiding high-fat foods during dose increases, staying hydrated, and reporting persistent vomiting, severe abdominal pain, yellowing skin or signs of an allergic reaction promptly.
Questions to Ask Your Prescriber
- Which approved option best matches my health conditions and goals?
- What results are realistic, and when will we decide whether it is working?
- What are the most likely side effects, and how should I manage them?
- Will this interact with anything I take now?
- What happens if I stop? Do I need a maintenance plan?
- How much will it cost, and is there insurance or prior-authorisation support?
Frequently Asked Questions
What is the safest weight-loss medicine?
No single medicine is safest for everyone. Safety depends on your health history, other medicines and monitoring. A clinician can match the approved options to your profile.
Which approved weight-loss drug works best?
In clinical trials, tirzepatide has produced the largest average weight loss, followed by semaglutide, then older oral medicines. Individual results vary, and tolerability matters as much as average numbers.
Are weight-loss pills safe without a prescription?
Orlistat 60 mg (alli) is an FDA-approved over-the-counter option. Most other pills sold without a prescription are supplements, which are not approved for weight loss and sometimes contain hidden drugs.
Can I take weight-loss medicine if I am on opioids?
Contrave is generally not suitable because naltrexone blocks opioids. Other options may be possible but need medical review. Never combine products without asking your prescriber or pharmacist.
Is Ozempic approved for weight loss?
Ozempic is semaglutide approved for type 2 diabetes. The same active ingredient is sold as Wegovy for chronic weight management. Prescribing Ozempic for weight loss is off-label.
Is phentermine safe long term?
Phentermine is approved only for short-term use. Longer use is sometimes prescribed, but it requires close monitoring of blood pressure and heart rate.
Do I have to take these medicines forever?
Obesity is a chronic condition, and weight often returns after stopping many of these medicines. Duration is a shared decision between you and your clinician.
Stopping, Switching and Maintaining
Two situations deserve planning in advance. The first is switching: moving between GLP-1 medicines, or from an injection to a pill, often involves a specific dose conversion, so never improvise with leftover supplies. The second is stopping. Many people regain part of the weight after discontinuation, so clinicians discuss maintenance strategies such as a lower dose, continued nutrition coaching, strength training and regular weigh-ins. If side effects, cost or life events force a pause, tell your prescriber early. A short conversation can avoid an abrupt, unmanaged stop.
Bottom Line
The approved toolbox for weight management has never been broader or better supported by evidence. The most important steps are to choose an approved product, buy it through a legitimate pharmacy, have a clinician check your history and medicines, and measure progress at planned intervals. If a product promises prescription-level results without a prescription, treat that promise as a warning.
Medical disclaimer: This article is educational and not a substitute for professional medical advice. Approvals, labels and availability change; verify details with the FDA, your pharmacist and your prescriber.
